Results 161 to 170 of about 201,242 (267)

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Attitudes of healthcare workers toward recommending vaccination against herpes zoster: a study based on the health belief model and theory of planned behavior. [PDF]

Front Public Health
Wang B, Li Z.
europepmc   +1 more source

Herpes zoster rash illustrating dorsal ramus innervation in the C6 and C8 dermatomes: a report of two cases. [PDF]

AME Case Rep
Nomura H, Iwasaki H, Nomura S, Tanaka Y.
europepmc   +1 more source

Role of mucosal chemokines in the development of tissue-resident CD4⁺ and CD8⁺ T_RM cells to fend off herpes simplex infections. [PDF]

Front Immunol
Lekbach Y, Chentoufi AA, Prakash S, Karan S, Quadiri A, Hormi-Carver KK, Dorotta JC, BenMohamed L.   +7 more
europepmc   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

From Knowledge to Action: Enhancing Herpes Zoster Vaccine Uptake in Diabetic Patients Through Targeted Interventions. [PDF]

Vaccines (Basel)
Fabbri M, Cavalli G, Frassineti V, Di Bartolo P, Reali C, Bakken E, Morri M, Belloli G, Mancini G, Chiavarini M, Silvestrini G.   +10 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

The efficacy, immunogenicity and safety of a recombinant tetrameric gE-Fc fusion protein vaccine for herpes zoster in adults 40 years of age or older：a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Li J, Jin P, Quan Y, Gao X, Wei M, Cao X, Pan H, Shen H, Zhao L, Xu Q, Wang Z, Liu X, Xu J, Xu K, Wan W, Tong Y, Li Z, Xu S.   +17 more
europepmc   +1 more source

S1 guidelines of the German Society of Neurology for Viral Meningoencephalitis- AWMF Registration No.: 030-100. [PDF]

Neurol Res Pract
Meyding-Lamadé U, Craemer EM, Aydin K, Jacobi C, Wagner J, Pfausler B, Prange H, Schuchardt V, Mosthaf S, Mehling M, Klein M, Bassa B.   +11 more
europepmc   +1 more source

Oncolytic Vaccinia Virus‐HSP70‐shRNA Amplifies Viral Replication, ROS/Autophagy, and Immunity to Fight Colorectal Cancer

Cancer Science, EarlyView.
OncoVV‑shHSP70, a vaccinia virus silencing HSP70, demonstrated potent antitumor efficacy in colorectal cancer cell lines, as well as in syngeneic, xenograft, and humanized mouse models. In cell lines, oncoVV‑shHSP70 promoted viral oncolysis and cytokine production through a self‑reinforcing cycle of ROS‑autophagy. In both CT26 and SW620‑humanized mouse
Rentao Yuan, Ruikang Liu, Fangying Shao, Zheqi Cai, Yingfei Fang, Kan Chen, Yanrong Zhou, Ting Ye, Gongchu Li   +8 more
wiley   +1 more source